Shots:
- The approval is based on a P-III DAPA-CKD trial that evaluates the efficacy of Forxiga (10mg, qd in addition to SoC) vs PBO in 4304 patients with CKD Stage 2-4 & elevated urinary albumin excretion with & without T2D
- The results showed 39% reduction in risk of worsening of renal function, ESKD, CV or renal death & 31% from any cause, safety & tolerability were consistent with a well-established safety profile of the therapy
- The therapy is recently approved in the US for CKD in adults with & without T2D & is currently under review in Japan & other countries globally. The therapy is indicated as an adjunct to diet & exercise to improve glycemic control in adults with T2D & for HF with HFrEF
Click here to read full press release/ article | Ref: AstraZeneca | Image: The Scientist Magazine
The post AstraZeneca’s Forxiga (dapagliflozin) Receives EC’s Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D first appeared on PharmaShots.
